New hope for advanced cancer patients in early safety trial

NCT ID NCT04419532

First seen Mar 22, 2026 · Last updated May 14, 2026 · Updated 7 times

Summary

This early-phase study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants receive the drug and are monitored for side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cancer Institute Hospital of JFCR

    Kōtoku, 135-8550, Japan

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • National Cancer Center Hospital

    Chūōku, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa, 277-8577, Japan

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 2C1, Canada

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio, 45219, United States

Conditions

Explore the condition pages connected to this study.